Condition: Physiological Reactivity to Cues · Physical Exercise · Sponsor: University of Illinois at Chicago
Patients with pancreatic cancer receiving neoadjuvant chemotherapy often experience functional decline, treatment interruptions, and clinical deterioration, and these risks may be amplified when frailty is present.
This description comes directly from the study's public registry record.
Aslam Ejaz, MD · 312 996 6666 · aejaz@uic.edu
Zoey Zhou · 312-996-6666 · zyzhou@uic.edu
Always discuss trial participation with your own doctor first.
| University of Illinois Clinical Cancer Center | Chicago, Illinois, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07647250